Influence of Albumin Treatment Duration on Outcome of Terlipressin Therapy in Patients With HRS-AKI

What Was Tested

The paper reports a study of Terlipressin, published as an observational study.

Volume expansion with albumin is recommended to establish a diagnosis of hepatorenal syndrome-acute kidney injury (HRS-AKI).

The optimal duration of albumin administration is debated and requires balancing the risk of overtreatment with the need for timely diagnosis and treatment.

Therefore, this study aimed to compare the impact of different albumin treatment durations on terlipressin response and the prognosis of patients with HRS-AKI treated with terlipressin and albumin.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

This multicenter, retrospective secondary analysis included patients with suspected HRS-AKI who were treated with terlipressin and albumin at 12 German centers.

One hundred forty five patients were available for further analysis.

How the Study Was Run

In design terms this was a multicenter study.

Running at several centres spread the Terlipressin study over different clinics and patient groups.

The cohort was dichotomized into patients treated with albumin for < 24 h and for 24-60 h before initiation of terlipressin.

Patients were followed for treatment response to terlipressin, need for haemodialysis (HD), survival, or liver transplantation (LT).

What Was Measured

Topics PubMed links to this paper include Acute Kidney Injury, Albumins, Germany, Hepatorenal Syndrome, Liver Transplantation, Prognosis and Renal Dialysis.

Author keywords: HRS‐AKI, KDIGO, ascites, cirrhosis, portal hypertension and terlipressin.

What This Means in Plain Language

The paper is a multicenter study of Terlipressin.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Liver international : official journal of the International Association for the Study of the Liver), a journal based in United States.

More context: the Terlipressin compound page, all human trials.